Analytical Data
-
基因名
MAGEF1
- Application
-
别名
MAGEF1；Melanoma-associated antigen F1
-
种属
Human
-
表达系统
E. coli
-
标签
His tag N-Terminus
-
纯度
Greater than 90% as determined by SDS-PAGE.
-
蛋白编号
Q9HAY2
-
表达区间
1-307aa
-
氨基酸序列
MLQTPESRGLPVPQAEGEKDGGHDGETRAPTASQERPKEELGAGREEGAAEPALTRKGARALAAKALARRRAYRRLNRTVAELVQFLLVKDKKKSPITRSEMVKYVIGDLKILFPDIIARAAEHLRYVFGFELKQFDRKHHTYILINKLKPLEEEEEEDLGGDGPRLGLLMMILGLIYMRGNSAREAQVWEMLRRLGVQPSKYHFLFGYPKRLIMEDFVQQRYLSYRRVPHTNPPEYEFSWGPRSNLEISKMEVLGFVAKLHKKEPQHWPVQYREALADEADRARAKARAEASMRARASARAGIHLW
-
分子量
35.2 kDa
-
内毒素
< 1.0 EU per μg protein as determined by the LAL method.
-
性状
Freeze-dried powder
-
缓冲液
PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300.
-
复溶方法
Reconstitute in ddH2O to a concentration of 0.1-0.5 mg/mL. Do not vortex.
- 个性化定制
-
稳定性测试
The thermal stability is described by the loss rate. The loss rate was determined by accelerated thermal degradation test, that is, incubate the protein at 37℃ for 48h, and no obvious degradation and precipitation were observed. The loss rate isless than 8% within the expiration date under appropriate storage condition.
-
保存条件 & 期限
Samples are stable for up to twelve months from date of receipt at -20℃ to -80℃. Store it under sterile conditions at -20℃ to -80℃. It is recommended that the protein be aliquoted for optimal storage. Avoid repeated freeze-thaw cycles.
-
运输条件
In general, recombinant proteins are supplied as lyophilized powder and shipped at ambient temperature. For bulk packages, the proteins are provided as frozen liquid and shipped with blue ice, unless otherwise requested by the customer.
Quality inspection process
Related Products
Protein Description
MAGEF1 (Melanoma Antigen Family E Member 1) is a member of the MAGE (Melanoma Antigen Gene) family, known for its role in immune response and potential implications in cancer immunotherapy. This gene is predominantly expressed in testicular germ cells and various malignant tissues, making it a target of interest in cancer research. MAGEF1 is involved in regulating key cellular processes, including apoptosis and cell proliferation, which are critical in tumorigenesis. Research indicates that MAGEF1 may contribute to tumor evasion mechanisms, allowing cancer cells to escape immune detection. Given its restricted expression in normal tissues and enhanced expression in cancer, MAGEF1 presents a promising candidate for developing cancer vaccines and targeted therapies. Recent studies have focused on the production and characterization of recombinant MAGEF1 proteins to elucidate their structure-function relationships, interactions with immune cells, and potential as neoantigens. Understanding the precise role of MAGEF1 in tumor biology and its interactions with the immune system is crucial for harnessing its potential in novel therapeutic approaches. Overall, the ongoing research into MAGEF1 recombinant proteins aims to advance personalized immunotherapies, improve cancer treatment outcomes, and expand the therapeutic repertoire against various malignancies.
